Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

Phase 3

Completed

Conditions: Episodic Migraine

Interventions: Drug: Standard of Care (SOC) Migraine Preventive Medication
Drug: Atogepant

Registration Number: NCT03700320

Lead Sponsor: Allergan

Brief Summary: This study will evaluate safety and tolerability of treatment with atogepant for the prevention of episodic migraine over the course of one year.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 744

Inclusion Criteria

Written informed consent and participant privacy information (e.g., written authorization for use and release of health and research study information) obtained from the participant prior to initiation of any study-specific procedures.
Participant is a candidate to be prescribed at least one of the protocol-defined acceptable oral SOC migraine prevention medications and the participant is willing to accept SOC treatment.
Participants must be using a medically acceptable and effective method of birth control during the course of the entire study,
At least a 1-year history of migraine with or without aura consistent with a diagnosis
Age of the participant at the time of migraine onset < 50 years
History of 4 to 14 migraine days per month on average in the 3 months prior to Visit 1

Exclusion Criteria

Difficulty distinguishing migraine headaches from tension-type or other headaches
Has a history of migraine accompanied by diplopia or decreased level of consciousness or retinal migraine
Has a current diagnosis of chronic migraine (CM), new persistent daily headache, trigeminal autonomic cephalgia (e.g., cluster headache), or painful cranial neuropathy
≥ 15 headache days per month on average across the 3 months prior to Visit 1
Usage of opioids or barbiturates > 2 days/month, triptans or ergots ≥ 10 days/month, or simple analgesics (e.g., aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen) ≥ 15 days/month in the 3 months prior to Visit 1 per investigator's judgment, or during the baseline period. For all participants, barbiturates are excluded 30 days prior to screening and during the baseline period. For participants randomized to atogepant, barbiturates are excluded through the duration of the study as well
Female participant is pregnant, planning to become pregnant during the course of the study, or currently lactating. Women of childbearing potential must have a negative urine pregnancy test
Any clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal (GI), or neurologic disease
Hypertension as defined by sitting systolic blood pressure (BP) > 160 millimeter of mercury (mm Hg) or sitting diastolic BP > 100 mm Hg at Visits 1 or Visit 2. Vital sign measurements that exceed these limits may be repeated only once.
At Visit 1, a user of recreational or illicit drugs or has had a history within the past year of drug or alcohol abuse or dependence
History of any GI prior procedures or GI conditions (e.g., diarrhea syndromes, inflammatory bowel disease) that may affect the absorption or metabolism of atogepant; participants with prior gastric bariatric interventions (e.g., Lap Band) which have been reversed are not excluded.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Oral SOC Migraine Preventive Medication	Standard of Care (SOC) Migraine Preventive Medication	Oral standard of care (SOC) medication recognized as safe and effective for the prevention of migraine, based on investigator's judgement in consultation with the participant.
Atogepant 60 mg	Atogepant	Atogepant 60 mg tablet taken orally, once daily for 52 weeks.

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With at Least 1 Treatment Emergent Adverse Event (TEAE)	From first dose up to the end of study (median treatment of 52 weeks) + 4 weeks follow-up	An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE is an AE that occurs or worsens after receiving investigational study drug.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With Clinically Significant Laboratory Values as Assessed by the Investigator	From first dose up to the end of study (median treatment of 52 weeks) + 4 weeks follow-up	Laboratory tests included tests of hematology, chemistry, and urinalysis. The investigator determined if the results were potentially clinically significant (PCS). Only categories with at least one participant are reported.
Percentage of Participants With Clinically Significant Electrocardiogram (ECG) Findings as Assessed by the Investigator	Up to Week 52	A standard 12-lead ECG was performed. The investigator determined if the result was potentially clinically significant. Only categories with at least one participant are reported.
Percentage of Participants With Clinically Significant Vital Sign Measurements as Assessed by the Investigator	From first dose up to the end of study (median treatment of 52 weeks + 4 weeks follow-up)	Vital sign measurements included sitting and standing blood pressure (BP), sitting and standing pulse rate, respiratory rate, temperature, and body weight. The investigator determined if the results were clinically significant. Only categories with at least one participant are reported.
Number of Participants With Most Severe Columbia-Suicide Severity Rating Scale (C-SSRS) Assessing Suicidal Ideation or Suicidal Behavior	Up to Week 52	The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. (Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior). Only the most severe suicidal ideation and the most severe suicidal behavior counted during the treatment period for at least 1 participant are reported.

Trial Locations

Locations (101): Clinical Research Advantage, Inc./Simon Williamson Clinic, PC
🇺🇸
Birmingham, Alabama, United States
Achieve Clinical Research, LLC
🇺🇸
Birmingham, Alabama, United States
Synexus Clinical Research US, Inc./East Valley Family Physicians PLC
🇺🇸
Chandler, Arizona, United States
Synexus Clinical Research US, Inc./Desert Clinical Research, LLC
🇺🇸
Mesa, Arizona, United States
Synexus Clinical Research US, Inc./Central Phoenix Medical Clinic, LLC
🇺🇸
Phoenix, Arizona, United States
Anaheim Clinical Trials, LLC
🇺🇸
Anaheim, California, United States
Hope Clinical Research
🇺🇸
Canoga Park, California, United States
Pharmacology Research Institute
🇺🇸
Los Alamitos, California, United States
Sun Valley Research Center, Inc.
🇺🇸
Imperial, California, United States
Irvine Center for Clinical Research
🇺🇸
Irvine, California, United States
Scroll for more (91 remaining)
Clinical Research Advantage, Inc./Simon Williamson Clinic, PC
🇺🇸Birmingham, Alabama, United States